Drug Profile
Research programme: antiviral vaccines - Profectus BioSciences
Alternative Names: Chikungunya virus vaccine - Profectus; filovirus MCM - Profectus; HCV vaccine - Profectus BioSciences; HPV vaccine - Profectus BioSciences; HSV vaccine - Profectus BioSciences; Preventative HIV rVSV vaccine - Profectus; rVSV-Ebola vaccine - Profectus; rVSV-QUAD; rVSV-Sudan; rVSV-VHF; rVSVN4CT1 Z Ebola; VesiculoVax rVSV-vectored Ebola/Marburg vaccine; VesiculoVax™-EEEV; VesiculoVax™-VEEV; Z EboV rVSVN4CT1Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Profectus Biosciences
- Developer Emergent BioSolutions; Profectus Biosciences; University of Texas Medical Branch
- Class AIDS vaccines; DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lassa fever
- No development reported Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Marburg virus disease; Venezuelan equine encephalomyelitis; Viral infections; Zika virus infection
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Chikungunya-virus-infections(Prevention) in USA (Parenteral, Injection)
- 28 May 2021 No recent reports of development identified for preclinical development in Eastern-equine-encephalomyelitis(Prevention) in USA (Parenteral)
- 28 May 2021 No recent reports of development identified for preclinical development in Ebola-virus-infections(Prevention) in USA (IM, Injection)